REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
Encore presentations will be presented as follows:ROCKVILLE, Md., Oct. 18, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present new interim data evaluating subretinal delivery of ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD) at the American Academy of Ophthalmology 2024 annual meeting. ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet AMD, diabetic retinopathy and other additional chronic retinal conditions.
馬里蘭州羅克維爾，2024年10月18日，REGENXBIO公司（納斯達克股票代碼：RGNX）今天宣佈將在美國眼科醫學學會2024年年會上提出評估ABBV-RGX-314亞視網膜下給藥治療雙側溼性年齡相關性黃斑變性（溼性AMD）患者的新中期數據。ABBV-RGX-314是一種正在與艾伯維公司合作開發的一次性AAV療法，用於治療溼性AMD、糖尿病視網膜病變和其他慢性視網膜疾病。
New data will be presented as follows:
新數據將如下呈現：
Title: Subretinal Delivery of Investigational ABBV-RGX-314 as a Gene Therapy for nAMD: First Time Results of a Fellow Eye Bilateral Dosing Study (abstract 30080148)
Presenter: Arshad Khanani M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates
Date/Time: Saturday, October 19, 2024, at 11:59 a.m. ET
標題：作爲nAMD基因療法的調查性ABBV-RGX-314亞視網膜下給藥：同側眼雙側劑量研究的首次結果（摘要30080148）
演講人：Sierra Eye Associates臨床研究主任Arshad Khanani m.D.萬.A.，FASRS
日期/時間：2024年10月19日（星期六），美國東部時間上午11:59
Encore presentations will be presented as follows:
重現演示將如下呈現：
Title: A Phase 2 Dose-Escalation Study Evaluating Suprachoroidal Delivery of Investigational ABBV-RGX-314 Gene Therapy for DR (abstract 30078795)
Presenter: Arshad Khanani M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates
Date/Time: Monday, October 21, 2024, at 10:45 a.m. ET
標題：評估調查性ABBV-RGX-314基因治療DR的視脈絡膜上給藥劑量逐步增加的2期研究（摘要30078795）
演講人：Sierra Eye Associates臨床研究主任Arshad Khanani m.D.萬.A.，FASRS
日期/時間: 2024年10月21日星期一，美國東部時間上午10:45
Title: Long-Term Follow-Up Study Results from the Investigational Phase I/IIa ABBV-RGX-314 Subretinal Delivery Gene Therapy Program in nAMD (abstract 30079480)
Presenter: Philip P. Storey, M.D., Austin Retina Associates
Date/Time: Monday, October 21, 2024, at 12:45 p.m. ET
標題: 來自ABBV-RGX-314潛在I/IIa亞美-314網膜下輸送基因治療方案的長期隨訪研究結果（摘要30079480）
主講人: Philip P. Storey博士，Austin視網膜聯盟
日期/時間: 2024年10月21日星期一，美國東部時間下午12:45
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit .
關於REGENXBIO公司。
regenxbio是一家領先的臨床階段生物技術公司，致力於通過基因療法的治癒潛力改善生活。自2009年成立以來，regenxbio公司一直是AAV療法的開拓者，這是一種創新型基因療法藥物。regenxbio正在推進一系列用於視網膜和罕見疾病的AAV療法，包括與艾伯維公司合作開發的治療AMD溼性型和糖尿病視網膜病的ABBV-RGX-314，用於治療杜興氏肌無力的RGX-202以及用於治療MPS II的RGX-121。數千名患者已接受regenxbio的AAV療法平台治療，包括諾華公司的ZOLGENSMA用於治療脊髓性肌萎縮症的兒童。作爲一次性治療，AAV療法有可能改變數百萬人的醫療傳遞方式。欲了解更多信息，請訪問 .
Zolgensma is a registered trademark of Novartis Gene Therapies.
Zolgensma是諾華基因療法的註冊商標。
Contacts:
Dana Cormack
Corporate Communications
[email protected]
聯繫人：
達納Cormack
企業通訊
[email protected]
George E. MacDougall
Investor Relations
[email protected]
George E. MacDougall
投資者關係
[email protected]
SOURCE REGENXBIO Inc.
來源REGENXBIO公司。
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
